Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation

Cancer stem cells (CSCs) have tumor initiation, self-renewal, metastasis and chemo-resistance properties in various tumors including colorectal cancer. Targeting of CSCs may be essential to prevent relapse of tumors after chemotherapy. Phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signals are central regulators of cell growth, proliferation, differentiation, and apoptosis. These pathways are related to colorectal tumorigenesis. This study focused on PI3K and mTOR pathways by inhibition which initiate differentiation of SW620 derived CSCs and investigated its effect on tumor progression. By using rapamycin, LY294002, and NVP-BEZ235, respectively, PI3K and mTOR signals were blocked independently or dually in colorectal CSCs. Colorectal CSCs gained their differentiation property and lost their stemness properties most significantly in dual-blocked CSCs. After treated with anti-cancer drug (paclitaxel) on the differentiated CSCs cell viability, self-renewal ability and differentiation status were analyzed. As a result dual-blocking group has most enhanced sensitivity for anti-cancer drug. Xenograft tumorigenesis assay by using immunodeficiency mice also shows that dual-inhibited group more effectively increased drug sensitivity and suppressed tumor growth compared to single-inhibited groups. Therefore it could have potent anti-cancer effects that dual-blocking of PI3K and mTOR induces differentiation and improves chemotherapeutic effects on SW620 human colorectal CSCs.

[1]  H. Shang,et al.  Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline , 2015, Oncotarget.

[2]  M. Todaro,et al.  By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy , 2014, Oncotarget.

[3]  G. Botchkina.  Colon cancer stem cells--from basic to clinical application. , 2013, Cancer letters.

[4]  J. Christensen,et al.  Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation , 2013, PloS one.

[5]  A. Pandurangan,et al.  Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[6]  C. Eng,et al.  The promise of mTOR inhibitors in the treatment of colorectal cancer , 2012, Expert opinion on investigational drugs.

[7]  L. Nicholson,et al.  Cancer stem cells: in the line of fire. , 2012, Cancer treatment reviews.

[8]  P. Schultz,et al.  Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma , 2010, Clinical Cancer Research.

[9]  Karen Curtin,et al.  Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. , 2010, Carcinogenesis.

[10]  Chan‐Wha Kim,et al.  Transgelin promotes migration and invasion of cancer stem cells. , 2010, Journal of proteome research.

[11]  G. Koehl,et al.  Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APCMin/+ mice , 2010, Oncogene.

[12]  P. Palozza,et al.  Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells. , 2009, Cancer letters.

[13]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[14]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[15]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[16]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[17]  B. Ang,et al.  Cancer stem cell: target for anti‐cancer therapy , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  H. Clevers,et al.  Identification of stem cells in small intestine and colon by marker gene Lgr5 , 2007, Nature.

[19]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[20]  J. Rich,et al.  Cancer stem cells in radiation resistance. , 2007, Cancer research.

[21]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[22]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[23]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[24]  M. Noble,et al.  Cancer stem cells. , 2006, The New England journal of medicine.

[25]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[26]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[27]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[28]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.

[29]  Young Soo Kim,et al.  In vitro trans-differentiation of rat mesenchymal cells into insulin-producing cells by rat pancreatic extract. , 2005, Biochemical and biophysical research communications.

[30]  G. Mills,et al.  Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. , 2005, Cancer research.

[31]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[32]  M. Oshimura,et al.  PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.

[33]  J. Green.  Mouse models of human breast cancer: evolution or convolution? , 2003, Breast Cancer Research.

[34]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[35]  N. Kneteman,et al.  Therapeutic Monitoring of Rapamycin: A New Immunosuppressive Drug , 1993, Therapeutic drug monitoring.

[36]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[37]  John F. Timms,et al.  Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer , 2001 .